Cargando…

Antiangiogenic agents targeting different angiogenic pathways have opposite effects on tumor hypoxia in R-18 human melanoma xenografts

BACKGROUND: Studies comparing the effect of antiangiogenic agents targeting different angiogenic pathways are sparse. The purpose of this study was to compare the effect of properdistatin and sunitinib treatment in a preclinical model of malignant melanoma. Properdistatin is a small peptide derived...

Descripción completa

Detalles Bibliográficos
Autores principales: Gaustad, Jon-Vidar, Simonsen, Trude G., Andersen, Lise Mari K., Rofstad, Einar K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5469039/
https://www.ncbi.nlm.nih.gov/pubmed/28606060
http://dx.doi.org/10.1186/s12885-017-3404-4
_version_ 1783243507782123520
author Gaustad, Jon-Vidar
Simonsen, Trude G.
Andersen, Lise Mari K.
Rofstad, Einar K.
author_facet Gaustad, Jon-Vidar
Simonsen, Trude G.
Andersen, Lise Mari K.
Rofstad, Einar K.
author_sort Gaustad, Jon-Vidar
collection PubMed
description BACKGROUND: Studies comparing the effect of antiangiogenic agents targeting different angiogenic pathways are sparse. The purpose of this study was to compare the effect of properdistatin and sunitinib treatment in a preclinical model of malignant melanoma. Properdistatin is a small peptide derived from the thrombospondin-1 domain of the plasma protein properdin, and sunitinib is a tyrosine kinase inhibitor targeting several receptors including the vascular endothelial growth factor receptors. METHODS: R-18 human melanoma xenografts growing in dorsal window chambers were treated with properdistatin, sunitinib, or vehicle. Parameters describing the morphology of tumor vasculature were assessed from high-resolution transillumination images, and BST (blood supply time; the time needed for arterial blood to flow from the main supplying artery to downstream microvessels) was assessed from first-pass imaging movies recorded after a bolus of fluorescence-labeled dextran had been administered intravenously. Tumor hypoxia was assessed from immunohistochemical preparations of the imaged tissue by using pimonidazole as a hypoxia marker. RESULTS: Properdistatin treatment selectively removed small-diameter vessels and reduced BST, whereas sunitinib treatment reduced the density of small- and large-diameter vessel similarly and did not change BST. These observations imply that properdistatin treatment reduced geometric resistance to blood flow and improved vascular function, whereas sunitinib treatment did not affect vascular function. Accordingly, sunitinib-treated tumors showed higher hypoxic fractions than properdistatin-treated tumors. CONCLUSIONS: Properdistatin and sunitinib both inhibited angiogenesis, but had distinctly different effects on vascular morphology, vascular function, and extent of hypoxia in R-18 human melanoma xenografts. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-017-3404-4) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5469039
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-54690392017-06-14 Antiangiogenic agents targeting different angiogenic pathways have opposite effects on tumor hypoxia in R-18 human melanoma xenografts Gaustad, Jon-Vidar Simonsen, Trude G. Andersen, Lise Mari K. Rofstad, Einar K. BMC Cancer Research Article BACKGROUND: Studies comparing the effect of antiangiogenic agents targeting different angiogenic pathways are sparse. The purpose of this study was to compare the effect of properdistatin and sunitinib treatment in a preclinical model of malignant melanoma. Properdistatin is a small peptide derived from the thrombospondin-1 domain of the plasma protein properdin, and sunitinib is a tyrosine kinase inhibitor targeting several receptors including the vascular endothelial growth factor receptors. METHODS: R-18 human melanoma xenografts growing in dorsal window chambers were treated with properdistatin, sunitinib, or vehicle. Parameters describing the morphology of tumor vasculature were assessed from high-resolution transillumination images, and BST (blood supply time; the time needed for arterial blood to flow from the main supplying artery to downstream microvessels) was assessed from first-pass imaging movies recorded after a bolus of fluorescence-labeled dextran had been administered intravenously. Tumor hypoxia was assessed from immunohistochemical preparations of the imaged tissue by using pimonidazole as a hypoxia marker. RESULTS: Properdistatin treatment selectively removed small-diameter vessels and reduced BST, whereas sunitinib treatment reduced the density of small- and large-diameter vessel similarly and did not change BST. These observations imply that properdistatin treatment reduced geometric resistance to blood flow and improved vascular function, whereas sunitinib treatment did not affect vascular function. Accordingly, sunitinib-treated tumors showed higher hypoxic fractions than properdistatin-treated tumors. CONCLUSIONS: Properdistatin and sunitinib both inhibited angiogenesis, but had distinctly different effects on vascular morphology, vascular function, and extent of hypoxia in R-18 human melanoma xenografts. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-017-3404-4) contains supplementary material, which is available to authorized users. BioMed Central 2017-06-12 /pmc/articles/PMC5469039/ /pubmed/28606060 http://dx.doi.org/10.1186/s12885-017-3404-4 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Gaustad, Jon-Vidar
Simonsen, Trude G.
Andersen, Lise Mari K.
Rofstad, Einar K.
Antiangiogenic agents targeting different angiogenic pathways have opposite effects on tumor hypoxia in R-18 human melanoma xenografts
title Antiangiogenic agents targeting different angiogenic pathways have opposite effects on tumor hypoxia in R-18 human melanoma xenografts
title_full Antiangiogenic agents targeting different angiogenic pathways have opposite effects on tumor hypoxia in R-18 human melanoma xenografts
title_fullStr Antiangiogenic agents targeting different angiogenic pathways have opposite effects on tumor hypoxia in R-18 human melanoma xenografts
title_full_unstemmed Antiangiogenic agents targeting different angiogenic pathways have opposite effects on tumor hypoxia in R-18 human melanoma xenografts
title_short Antiangiogenic agents targeting different angiogenic pathways have opposite effects on tumor hypoxia in R-18 human melanoma xenografts
title_sort antiangiogenic agents targeting different angiogenic pathways have opposite effects on tumor hypoxia in r-18 human melanoma xenografts
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5469039/
https://www.ncbi.nlm.nih.gov/pubmed/28606060
http://dx.doi.org/10.1186/s12885-017-3404-4
work_keys_str_mv AT gaustadjonvidar antiangiogenicagentstargetingdifferentangiogenicpathwayshaveoppositeeffectsontumorhypoxiainr18humanmelanomaxenografts
AT simonsentrudeg antiangiogenicagentstargetingdifferentangiogenicpathwayshaveoppositeeffectsontumorhypoxiainr18humanmelanomaxenografts
AT andersenlisemarik antiangiogenicagentstargetingdifferentangiogenicpathwayshaveoppositeeffectsontumorhypoxiainr18humanmelanomaxenografts
AT rofstadeinark antiangiogenicagentstargetingdifferentangiogenicpathwayshaveoppositeeffectsontumorhypoxiainr18humanmelanomaxenografts